Live WebinarNO PAIN for everyone – the modern prophylaxis concept of today
03 Aug 2019, 08:00 AM Berlin
Dr. Wong Li Beng
Soon to be available to dental professionals worldwide, the new system is intended to make treatments faster, as well as more straightforward and predictable. Achieving this required challenging conventional techniques in implantology. In order to address some of the shortcomings of current protocols, Nobel Biocare N1 was designed from the ground up according to biological principles and keeping patient needs in mind. In collaboration with a group of international researchers and clinicians, Nobel Biocare is now bringing this long-anticipated new system, which was created through over six years of scientific and clinical refinement, to the market.
The entire Nobel Biocare N1 system, from planning to delivery of the prosthesis, was created to streamline workflows and enhance patient comfort. Going beyond a new implant design, Nobel Biocare is also redefining site preparation with the introduction of the OsseoShaper, a new, innovative alternative to conventional drilling protocols. Experience gained from over 18 months of clinical evaluations of the Nobel Biocare N1 concept with an early ambassador group has already indicated promising results in terms of the method’s effectiveness.
Fully embodying the new Mucointegration concept, the Xeal and TiUltra surfaces will be available on the Nobel Biocare N1 implant system from the start. With the help of their specially tailored surface chemistry and topography, the Nobel Biocare N1 TiUltra implants and Xeal abutments will thus be beneficial for optimised tissue integration.
Nobel Biocare N1 will be further integrated into the digital workflow with DTX Studio, giving dental professionals more opportunities to provide patients with teeth in a shorter time.
“Our Nobel Biocare N1 system is a real breakthrough in almost every aspect of the treatment workflow,” said Nobel Biocare President Hans Geiselhöringer. “With the help of our early ambassador group, we have collected over 18 months of clinical experience on the Nobel Biocare N1 concept as well as the unique implant site preparation technique. The feedback we have received from clinicians experiencing the system for the first time here in Madrid has been extremely positive. I am more than convinced that the system will be able to set new standards for the industry,” he added.
Nobel Biocare N1 will first be available to clinicians in European Economic Area markets later in 2019, followed by additional markets—pending regulatory approval.
More information about Nobel Biocare N1 is also available at www.nobelbiocare.com/n1.